Mazdutide for Alcoholism

This trial aims to test a new treatment called mazdutide for people with alcohol use disorder (AUD). Participants will receive either mazdutide, administered as an injection under the skin, or a placebo, which mimics the real treatment. The trial spans up to 36 weeks, including screening and follow-up. Suitable candidates have a current AUD diagnosis and have not used specific AUD medications in the past 30 days. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.

The trial requires that you have not taken any medication for alcohol use disorder in the last 30 days. It does not specify about other medications, so it's best to discuss your current medications with the trial team.

Research has shown that mazdutide has been tested in people for other uses, helping to control blood sugar and reduce body weight. These studies suggest it is generally safe for most people. Although detailed information on side effects is limited, its progression to a Phase 2 study indicates it passed initial safety tests. This suggests it was safe enough in earlier trials to warrant further testing. However, as with any new treatment, unknown risks may exist. Participants might experience some side effects, but the study team will closely monitor them.¹²³⁴⁵

Unlike current treatments for alcoholism, such as behavioral therapies or medications like naltrexone and acamprosate, Mazdutide offers a novel approach by being administered subcutaneously. Researchers are excited about Mazdutide because it targets the condition in a different way, potentially offering more effective results. This treatment could provide a new option for those who have not found success with existing therapies, expanding the possibilities for managing alcoholism.

Research has shown that mazdutide, which participants in this trial may receive, might help treat alcohol use disorder (AUD). In a small study, six patients with AUD who took semaglutide, a similar drug, showed significant improvement. These patients drank less alcohol while using semaglutide. Researchers believe mazdutide works similarly, possibly affecting brain chemicals that control cravings and impulse control. Although more research is needed, these early results suggest that mazdutide could help reduce alcohol use in people with AUD.¹³⁵⁶⁷